ASCT2 Inhibitor

Lc-BPE is the highest affinity novel chemical tool for characterizing the role of Alanine-Serine-Cysteine Transporter 2 (ASCT2), a sodium-dependent transporter in a variety of tissues, in cancer and other diseases from this study.

Contributors

Inventor	Institute
Christof Grewer	Binghamton University

Cat. #:	160702
Tool sub type:	Inhibitor
Research Fields:	Genetics
Application:	molecular docking, electrophysiology, transport assays in proteoliposomes and cryo-EM structure determination of ASCT2
Purpose:	Inhibitor

Alternate name:	L-cis hydroxyproline biphenyl ester (Lc-BPE)
Selectivity:	Stereoselective

Primary target:	NA

Shipping conditions:	Dry Ice

References:	doi: https://doi.org/10.1101/2020.05.29.124305

Unfortunately this tool is not currently available through our online checkout process. Please contact our team directly to obtain further information on accessing this tool.

Enquire about this Tool

If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Request a license

Get support

New to CancerTools?

We are a trusted, non-profit platform for cancer research products, part of Cancer Research UK – by sourcing your cancer research tools from us you help fund future cancer research.

Find out more

Related Tools for Small molecules

Cat. #

Tool Name

151712

CDK7 inhibitor BS-181 Small Molecule (Tool Compound)

Key Info

Cat. #:	151712
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	BS-181 is stable in vivo with a plasma elimination half-life in mice of 405 minutes after i.p. administration of 10 mg/kg. BS-181 inhibits the growth of MCF-7 xenografts in the nude mice model in a dose-dependent manner, with 25% and 50% reduction in tumor growth after 2 weeks of treatment at 10 mg/kg/day and 20 mg/kg/day, respectively without apparent toxicity. BS-181 is a small molecule inhibitor of CDK7 in a cell-free environment, which displays more potential activity than roscovitine with IC 50 of 510 nM. Among the CDKs and other 69 kinases from many different classes, BS-181 shows high inhibitory selectivity for CDK7, inhibits CDK2 at concentrations lower than 1 ÎźM which being inhibited 35-fold less potently (IC50 with 880 nM) than CDK7, shows slight inhibition for CDK1, CDK4, CDK5, CDK6 and CDK9 with IC50 values higher than 3.0 ÎźM, and only shows inhibition for several kinases from other classes at high concentrations (>10 ÎźM). BS-181 promotes cell cycle arrest and inhibits the cancer cell growth of a range of tumor types, including breast, lung, prostate and colorectal cancer with IC50 in the range of 11.5-37 ÎźM. In MCF-7 cells, BS-181 inhibits the phosphorylation of the CDK7 substrate RNA polymerase II COOH-terminal domain (CTD), and promotes cell cycle arrest and apoptosis to inhibit the growth of cancer cell lines.

View Tool

151832

LIMK inhibitor CRT0105950 Small Molecule (Tool Compound)

Key Info

Cat. #:	151832
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The compounds exhibit low uM potency in breast cancer cells showing dose dependent inhibition of phosphorylation of the LIMK substrate cofilin. Treatment of MDA-MB-231 breast cancer cells with the compounds significantly reduces their ability to invade a matrigel plug in an inverse in vitro invasion assay. Furthermore, the inhibitors effectively reduce fibroblast-led collective invasion in a co-culture organotypic model.

View Tool

151843

AKR1C3 inhibitor CRT0036521 Small Molecule (Tool Compound)

Key Info

Cat. #:	151843
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The compounds showed good cellular potency, as measured by inhibition of AKR1C3 metabolism of a known dinitrobenzamide substrate, with a broad rank order between enzymic and cellular activity, but amide analogues were more effective than predicted by the cellular assay. displays potency in a cellular assay, blocking the ability of AKR1C3 to metabolize a proven substrate.

View Tool

152544

Protein Kinase D inhibitor CRT5 (CRT0066051) Small Molecule (Tool Compound)

Key Info

Cat. #:	152544
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	PLEASE NOTE THAT THIS COMPOUND IS TOXIC IN VIVO. CRT5 blocks phosphorylation of PKD1 on Ser916 and PKD2 on Ser876, but does not affect PKC-dependent PKD phosphorylation or PKD autophosphorylation.1 It also decreases VEGF-induced endothelial migration, proliferation, and tubulogenesis.

View Tool

152754

CDK2 inhibitor NU6301 Small Molecule (Tool Compound)

Key Info

Cat. #:	152754
Sub-type:	Inhibitor
Availability:	Please enquire for quantities and pricing
Application:	The prodrug NU6301 rapidly generated NU6102 in vitro in mouse plasma, and tumour NU6102 levels in vivo consistent with activity in vitro. Eight or 12 hourly dosing of 120 mg/kg NU6301 for 10 days was well tolerated in SKUT-1B tumour-bearing mice and inhibited Rb phosphorylation in tumour tissue. Two (8 hourly dosing) and 3 (12 hourly dosing) day tumour growth delay was observed (p=0.04 and p=0.007, respectively) following NU6301 administration. NU6102 selectively inhibited the growth of CDK2 WT (wild type) versus KO MEFs (knockout mouse embryo fibroblasts) (GIââ (concentration required to inhibit cell growth by 50%) 14 ÎźM versus >30 ÎźM), and was more growth-inhibitory in p53 mutant or null versus p53 WT cells (p=0.02), and in Rb (retinoblastoma protein) WT SKUT-1B versus SKUT 1 Rb deficient cells (p=0.01). In SKUT-1B cells NU6102 induced a G2 arrest, inhibition of Rb phosphorylation and cytotoxicity (LCââ 2.6 ÎźM for a 24h exposure).

View Tool

By Category

By Cancer Type

More

ASCT2 Inhibitor

Contributors

Related Tools for Small molecules

Tool enquiry